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966 The Journal of Thoracic and CardioIn this issue, McConnell and colleagues1 report a detailed examination of theimpact of autologous skeletal myoblast transplantation in a chronic ischemiccardiomyopathy model in sheep. They injected the cells prepared by GenVec,
Inc, at multiple sites in the infarct zone. They concluded that cardiac contractility
was not improved, but cell implantation prevented ventricular dilation. The study
highlights several important issues in cardiac cell therapy and its future in clinical
application.
Most preclinical reports have demonstrated improvement in systolic and diastolic
properties after cell transplantation.2 According to McConnell and colleagues,1 how-
ever, the predominant impact of myoblast implantation was not on systolic function.
Their finding could be related to the data analysis. For example, a significant enhance-
ment of cardiac performance might have been detected if they had made pressure
and volume measurements at lower volumes and if they had performed a more
robust statistical analysis (an analysis of covariance).
In this study, McConnell and colleagues1 reported at 6 weeks a 21% reduction in
end-systolic volume index (ESVI) in cell-transplanted sheep relative to control
sheep (98  18 mL/m2 vs 124  15 mL/m2), consistent with observations by other
investigators.1,3 Increased ESVI, independent of ejection fraction, has been associ-
ated with a marked increase in mortality in patients after myocardial infarction.4 In
patients undergoing surgical ventricular restoration for dilated ischemic cardiomy-
opathy, a preoperative ESVI lower than 80 mL/m2 is associated with a 16% lower
mortality than is an ESVI greater than 120 mL/m2 (P  .001).5 Cardiac cell therapy
may therefore improve survival for patients not eligible for surgical revasculariza-
tion and ventricular remodeling by preventing progressive ventricular dilation.
McConnell and colleagues1 injected cryopreserved myoblasts. Cryopreservation
will extend the time available to harvest, process, and prepare the cells for implan-
tation. The cryopreserved cells may also be stored, thus increasing the flexibility of
timing of cell transplantation. In addition, some cells can be implanted, and the
remainder can be cryopreserved for repeated implantation in the future. Cell cryopreser-
vation may broaden the clinical applicability of cell transplantation.
On the other hand, the outcome of cardiac cell therapy is determined by the
number, vigor, and viability of injected cells.6 More advanced cell passages, abnormal
cell morphology combined with cryopreservation, negatively affect cell growth and
vigor.3,7 In addition, recent evidence suggests that the proportion of injected cells
surviving to engraft in the infarcted myocardium is low,8 and cryopreservation may
have contributed to the less impressive functional improvement found in this study.
The cells may leak out of the injected region and may be carried to other organs,
contributing to the rapid cell loss seen in the first 24 hours.8 Acute oxidative stress,
ongoing ischemia, and inflammation also reduce cell survival.9 In the report of
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spite a high viability may have limited the beneficial impact
of cell transplantation.
To improve survival and engraftment of the transplanted
cells, many investigators have combined cell transplantation
with protein or gene therapy. Injection of fibroblast growth
factor or vascular endothelial growth factor before cell
transplantation improved cell survival in infarcted myocar-
dium.10,11 Insulin growth factor 1 transfection (Figure 1),
heat shock preconditioning, and antiapoptotic treatment of
donor cells also augmented the benefits of cell transplanta-
tion.12,13 Genetic enhancement of donor cells before cryo-
preservation and growth factor enrichment of recipient
myocardium before cell delivery may improve the func-
tional benefit by enhancing cell survival.
As the report by McConnell and colleagues1 illustrates,
several aspects of cardiac cell therapy still require clarifi-
cation, including the optimal cell processing and delivery
techniques, the best timing of cell implantation, and the
protein or gene enhancements that will significantly im-
prove cell survival. Large animal investigations, such as this
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The Journal of Thoracifuture clinical trial design and determine the appropriate
role of cardiac cell therapy in the treatment of ischemic
heart disease.
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